

# Obstacles and Pitfalls of Endometriosis-Related Chronic Pelvic Pain Management: Trying to Alleviate the Burden

Laganà AS<sup>1\*</sup>, Salmeri FM<sup>2</sup>, Sofo V<sup>2</sup>, Pizzo A<sup>1</sup>, Retto G<sup>1</sup>, Sturlese E<sup>1</sup>, Granese R<sup>1</sup> and Triolo O<sup>1</sup>

<sup>1</sup>Department of Pediatric, Gynecological, Microbiological and Biomedical Sciences, University of Messina, Via C. Valeria 1, 98125 - Messina, Italy

<sup>2</sup>Department of Environmental Sciences, Safety, Territory, Food and Health, University of Messina, Via C. Valeria 1, 98125 - Messina, Italy

## Abstract

Chronic Pelvic Pain (CPP) could be defined as the presence of non-cyclic pain of 6 months duration or longer that localizes to the pelvis and is severe enough to cause functional disability and require medical or surgical treatment. Among women who undergo laparoscopy for CPP, endometriosis results in approximately 1/3 of the cases; conversely, among women who do not have CPP, endometriosis is present in only 5% of cases. Moreover, accumulating evidences support the opinion for which CPP has poor correlation with endometriosis stage, moderate correlation with isolated presence of ovarian endometrioma, strong correlation with Deep Infiltrating Endometriosis (especially if it affects bowel or urinary tract) and/or adhesion. Endometriosis-related CPP could arise through different pathways: one of the clearest reason is that endometriotic lesion could provoke a compression or infiltration of nerves; another possible causes of arising CPP could be represented by the increase of Nerve Growth Factor (NGF) in the endometriotic lesion area; last but not least, CPP could arise and be exacerbated also by inflammation of the peritoneal microenvironment. The hormonal therapies do not eliminate the endometriotic implants and, for this reason, stopping the treatment pelvic pain and other typical symptoms of endometriosis may recur and exacerbate the pre-treatment condition. The surgical treatment of endometriosis-related CPP is still not perfectly encoded, due to the unclear etiology and the different response to therapies. For these reasons, there is necessity of more efforts to create new non-invasive strategies that set a more accurate diagnosis and treatment of the causes of endometriosis-related CPP.

**Keywords:** Endometriosis; Chronic pelvic pain; Diagnosis; Medical treatment; Surgical treatment

## The Dimension of the Problem

Chronic Pelvic Pain (CPP) could be defined as the presence of non-cyclic pain of 6 months duration or longer that localizes to the pelvis and is severe enough to cause functional disability and require medical or surgical treatment [1]. It could be considered nowadays a deep health problem that challenges physicians all over the world. This because its aetiology is still unclear, the course of the disease could vary a lot among different patients and through time in the same patient, and the response to treatments is not every time successful. CPP affects deeply and negatively woman's quality of life, contributing not only to suffering, but also to marital and family problems, to problems related to the achievements of work tasks, and overall to disability in woman's role in modern society. Mathias et al. reported that among 5,263 U.S. women, 773 (14.7%) had CPP within the past 3 months, and that in 61% of the cases the aetiology was unknown. They underlined also that women diagnosed with endometriosis reported the most health distress, pain during or after intercourse, and interference with activities because of pain. It represents also a public financial problem, because deeply increases medical cost for diagnosis and therapy: just considering USA, it costs approximately \$881.5 million per year [2]. CPP aetiology could be related to different disease, such as urologic (recurrent and/or interstitial cystitis, complication after urologic surgery, nephrolithiasis, urolithiasis), gastrointestinal (irritable bowel syndrome, chronic inflammatory bowel disease, diverticulosis, polyposis), vascular, musculoskeletal, neurological, psychological. For this reason, actually the world medical literatures suggest to engage a multidisciplinary approach to this syndrome [3]. Just considering gynaecological and obstetric point of view, CPP could arise from a wide range of conditions, included presence of adhesions that can involve pelvic organs and walls, chronic cervical infection for cervical stenosis, post-surgical complication after cryo/laser/diathermy surgery for portio diseases, Pelvic Inflammatory Disease (PID), endometriosis and adenomyosis. Recent estimates suggest that in nearly 1/3 of the cases the reason for the pain seems to be due to endometriosis and in another third to adhesions [4]. According to Howard [5] there are

four of more common disorders associated with chronic pelvic pain (endometriosis, adhesions, irritable bowel syndrome, and interstitial cystitis). Moreover is it widely accepted that CPP could be due also to coexistence of interstitial cystitis and endometriosis in the same patient, the so-called "Evil Twins Syndrome". In order to assess the incidence of this condition, Chung et al. [6] collected 178 women with CPP who presented with bladder base/anterior vaginal wall and/or uterine tenderness, with or without irritative voiding symptoms. They found presence of endometriosis in 134 (75%) patients, and of interstitial cystitis in 159 (89%) patients. So, they suggest performing both laparoscopic and cystoscopic examinations concurrently with the patient anesthetized in the initial evaluation and treatment of CPP, in order to avoid unnecessary delay in making the diagnosis. The strict connection between urological and gynaecological diseases in the arising of CPP is confirmed also by another work by Stanford et al. [7], who collected 64 patients who underwent intravesical potassium sensitivity test (PST), cystoscopy with double-fill hydrodistension, physical examination for vulvar pain, pelvic pain/urgency/frequency (PUF) screening questionnaire and laparoscopy to assess the presence of peritoneal pathology. Their results seems to evidence that bladder pain, peritoneal pathology, and vulvar pain are independent risk factors of CPP, although a trend of severity was noted in patients who had worse symptoms (increased voids per day, urgency, pain, and PUF scores).

**\*Corresponding author:** Antonio Simone Laganà, Department of Pediatric, Gynecological, Microbiological and Biomedical Sciences, University of Messina. Via C. Valeria 1, 98125 Messina, Italy, Tel: (+39) 0902212183; Fax: (+39) 0902937083; E-mail: [antlagana@unime.it](mailto:antlagana@unime.it)

**Received** September 05, 2013; **Accepted** October 17, 2013; **Published** October 19, 2013

**Citation:** Laganà AS, Salmeri FM, Sofo V, Pizzo A, Retto G, et al. (2013) Obstacles and Pitfalls of Endometriosis-Related Chronic Pelvic Pain Management: Trying to Alleviate the Burden. J Pain Relief 2: 123. doi:10.4172/2167-0846.1000123

**Copyright:** © 2013 Laganà AS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Endometriosis and Chronic Pelvic Pain: A Strict Connection

Endometriosis is an estrogen-dependent disease [8] characterized by the ectopic presence and growth of functional endometrial tissue, glands, and stroma, outside the uterine cavity [9,10].

The disease most often affects the ovaries (up to 88% of all cases), uterine ligaments, fallopian tubes, rectum, cervical-vaginal region, and urinary tract. Urinary tract involvement is rare accounting for around 1-2% of all cases [11-13], of which 84% are found in the bladder [14]. However, endometriosis can be encountered in other abdominal organs such as the liver, pancreas, intestinal tract, spleen [15], gallbladder [16], the abdominal wall, and even the navel [17]. Endometriosis is classified depending on the number, size, and superficial and/or deep location of endometrial implants, plaques, endometriomas, and/or adhesions, as follows: stage I (minimal, 1-5 points), stage II (mild, 6-15 points), stage III (moderate, 16-40 points), and stage IV (severe, >40 points), following the revised American Society for Reproductive Medicine classification for Endometriosis [18]. Exerting a gross classification, endometriotic lesions could be divided into superficial peritoneal endometriosis, deeply infiltrating endometriosis (DIE) and ovarian (cystic) endometriosis [19]. Approximately 10% of women in reproductive age are estimated to be affected by this disease and its symptoms [20,21]. In particular, pelvic pain could be expressed in a wide range combination of type, such as dysmenorrhea, dyspareunia, dysuria, dyschezia, non-menstrual chronic pelvic-abdominal muscle pain [22]. In particular, accumulating evidence seems to confirm that; dysmenorrhea is independent of the macroscopic type of the lesions or their anatomical locations and may be related to recurrent cyclic micro bleeding in the implants [23]. According to Fauconier's group [24,25], only DIE lesions are associated with CPP, especially when this type of lesions involve bowel or urinary tract. Moreover, they found that endometriosis appears to be responsible for chronic pelvic pain symptoms in more than half of histologically confirmed cases [23]; nevertheless, it is very important to understand if CPP is caused by endometriosis, or endometriosis and CPP are separated entity. Among women who undergo laparoscopy for CPP, endometriosis results in approximately 1/3 of the cases; conversely, among women who do not have CPP, endometriosis is present in only 5% of cases [24-26]. Moreover, accumulating evidences support the opinion for which CPP has poor correlation with endometriosis stage [27], moderate correlation with isolated presence of ovarian endometrioma [28], strong correlation with DIE (especially if it affects bowel or urinary tract) [24] and/or adhesion [29]. The discrepancy observed between endometriosis stage and severity of CPP may be due to variable roles of different endometriosis-related pain mechanisms [30], and, in our opinion, also to the different influence that each mechanism have on the others. It is widely accepted in literature that there is no significant correlation between pain level and presence and size of ovarian endometriomas and extent, type, and site of peritoneal lesions [31]. Other Authors [32], on the contrary, state that endometriosis-related CPP could depend on location of endometriotic lesions. Similar finding was found by Arruda et al. [33] in a cohort of Brazilian women, in which endometriosis symptoms (especially CPP) were more severe in young women with delayed diagnosis. Considering that pain attributed to endometriosis occur even in women without endometriosis and pain and severity correlate poorly with lesion characteristics, accumulating evidence suggest that the diversified experience of pain may be due to the pain modulation activity of the Central Nervous System (CNS) [22].

## Endometriosis-Related Chronic Pelvic Pain Pathways

Endometriosis-related CPP may be due to nociceptive,

inflammatory, or neuropathic mechanisms, and probably all three of these mechanisms are important and interdependent [34]. Nociceptive stimuli could be exacerbate or decrease by reproductive (and consequently hormonal) status of the patient. In particular, estradiol (E2) is the best-defined mitogen for the growth and inflammation processes in the ectopic endometriotic tissue. The counterpart, represented by progesterone and progestins, is actually widely used in therapy to control endometriosis symptoms, both before and after surgery. Although the good result achieved with progestings, a portion of patients do not respond to this kind of treatment. This fail is probably related to overall reduction in the levels of progesterone receptors (PRs) and, in particular, to the lack of the PR isoform B (PR-B) typical of endometriotic implants [35]. On the other hand, progesterone resistance could depend, at least in part, by a loss of coregulation by Kruppel-like factor 9 (KLF9) on WNT-signaling component in human endometrial stromal cells [36]. Apart from the local environmental/inflammatory condition which could account for pain arising, CNS and Peripheral Nervous System (PNS) seem to influence each other, because CNS neurons responsive to stimulation of the reproductive tract also respond to stimulation of skin and other pelvic organs. Since this, it was observed a dynamic interconnection of these different stimuli entering the CNS via gateways through the spinal cord, dorsal column nuclei, and solitary nucleus, which can finally orchestrate the final response and pain perception of the patient [37]. CPP could arise through different pathways: one of the clearest reason is that endometriotic lesion could provoke a compression or infiltration of nerves [38]. Other possible causes of arising CPP could be represented by the increase of Nerve Growth Factor (NGF) in the endometriotic lesion area, and this may worsen the disease progression by two different way: on one hand it could improve "neural sprouting" and so create new painful afferents to the CNS, and, on the other hand, it could be considered itself a mediator that may exacerbate the CPP [39]. Moreover, accumulating evidence seems to confirm that endometriotic lesions could stimulate the growth of their own innervations by sensory and sympathetic fibers. CPP itself (related or not to endometriosis) seems to be associated with a distinctive pattern of proliferation of small-diameter nerve fibers through the myometrial stroma of uterus [40]. Interestingly, some authors [41] found that this innervations is denser in DIE lesions respect to other lesion type (and this could make relation with the fact that DIE lesions are frequently associated to CPP respect to other lesions type), although Others [42], on the contrary, state that there are no differences in detection of peritoneal "neural sprouting" (using immunocytochemistry staining with an antibody for neurofilament) between endometriotic patients and controls. Another cell mediator, the Vascular Endothelial Growth Factor (VEGF), could contribute to neoangiogenesis of the nerve vessels (in order to support "neural sprouting"), and so could enhance CPP [43]. Last but not least, CPP could arise and be exacerbated also by inflammation of the peritoneal microenvironment: in endometriosis immune alterations occur in the Peritoneal Fluid (PF) and peripheral blood, in part comparable to those proper of autoimmune diseases. It is widely reported an increase in the number but not in the function of macrophages, abnormalities in the functions and numbers of T and B lymphocytes, a reduction in number and activity of natural killer cells, apoptosis impairment, changes of cytokines and other soluble products in the peritoneal microenvironment [44-46]. In fact, it was showed a prevalence of Th1 profile (inflammatory) cytokines in the PF of women with endometriosis at minimal and mild stages whereas a Th2 profile (profibrotic, proangiogenic) cytokines prevailed in severe stages [47,48]. Moreover it was reported that the Fas/FasL apoptosis pathway system is dysregulated progressively throughout the course of the disease, with the result that endometriotic cells do not undergo

Fas/FasL-mediated apoptosis because they do not receive a death signal from Peritoneal Fluid Mononuclear Cells (PFMCs), so implanting themselves and surviving outside of the uterus. Paradoxically, endometriotic cells become themselves capable of killing PFMCs and this may allow their establishment in the peritoneum, which in turn becomes an immune privileged environment [49].

## Medical Treatment

Usually, the first step in treatment of CPP (related or not to endometriosis) is represented by analgesic drugs, but this medical treatment seems to be not effective, or, at least, there is no evidence that can alleviate pain in every patient. Among hormonal therapy, many drugs were tested to treat endometriosis: combined oral contraceptives (OCs, estrogens and progestins) [50], danazol [51], gestrinone, medroxyprogesterone acetate [52] and GnRH agonists have good chance to reduce endometriosis-related CPP, and have equal effectiveness to suppress ovarian production of estrogens and progesterone [53]. In particular, Szendei et al. [27] found that after laparoscopic surgery for endometriosis, the use of monophasic OC treatment could significantly reduce pain scores and the necessity of other radical operative solution. This finding is shared also by Gambone et al. [53] who moreover state that for women in whom endometriosis is the suspected cause of CPP the best approach seems to use medical therapy, including second-line therapies such as danazol, GnRH agonists, and progestins until there is necessity for surgery. The rationale of using progestins combined or not with estrogens is related to two different actions: on one hand, their anti-angiogenic, immunomodulatory and anti-inflammatory effects, and, on other hand, their action of inhibition of implantation and growth of refluxed menstrual endometrial debris [54]. About other kind of hormonal therapy, Leuprolide acetate (GnRH agonist) could be effective as pain reliever in women with endometriosis-associated CPP, although some Authors [55] state that it could be effective also in CPP in women without endometriosis. Also Intra Uterine System with Levonorgesterl (LNG IUS) could be useful and decrease endometriosis-associated CPP [56]. In any case, the hormonal therapies do not eliminate the endometriotic implants and, for this reason, stopping the treatment pelvic pain and other typical symptoms of endometriosis may recur and exacerbate the pre-treatment condition. New therapeutic strategies aimed at restoring PF homeostasis of the, through suppression of the production of proinflammatory cytokines such as TNF $\alpha$ , aromatase inhibition, and restriction of neoangiogenesis and "neural sprouting" [26,44]. In particular, a large body of evidence indicates that TNF $\alpha$  involved in macrophage activation, inflammatory change, and enhanced angiogenesis to develop endometriosis [57]. In addition to its proinflammatory functions, TNF $\alpha$  also stimulates the expression of matrix metalloproteinases in endometrial tissue [58], which are well-known to play a key- role in tissue remodeling and invasion of endometriotic lesions [59]. Confirming these assumptions, TNF- $\alpha$ -targeted suppression by specific drugs inhibits the development of endometriosis in baboons [60,61]. Regarding aromatase, the rate-limiting enzyme for the synthesis of estrogen, a bunch of evidence suggests that is aberrantly expressed in endometriotic implants. Epigenetic changes favoring the transcription of the aromatase gene in the endometrium allow endometrial cells to survive in ectopic locations by producing estrogens that spare them from destruction through activated macrophages [62,63]. So, in our opinion, also aromatase inhibitors could be considered a promising way of treatment (associated or not with other conventional therapy) to relieve endometriotic-associated pelvic pain.

## Surgical Treatment

The surgical treatment of endometriosis-related CPP is still

not perfectly encoded, due to the unclear etiology and the different response to therapies. Among the surgical techniques, laparoscopy is efficient for ovarian endometrioma excision or utero-sacral ligaments and vaginal deeply infiltrating endometriosis [64], whereas for massive bowel or bladder endometriotic lesions it could be useful open surgery (especially for surgeons who are not fully dedicated to gynecological mini-invasive surgery) or robotic surgery [65]. The most important concept approaching to endometriosis surgery is that excision of the lesions must be radical and complete, in order to restore proper anatomy and function of the pelvic organs [66]. Surprisingly, Sutton et al. [67] showed that CPP return sooner after surgery in patients with endometriosis at minimal and mild stages. Despite radical surgery, some Authors [64] found that pain re-arise and the patients undergo reoperation in 50-60% of the cases by 5 - 7 years. There is also evidence that re-operations rates are lower after hysterectomy than after operative laparoscopy [68], probably because uterus contain a great number of neural elements that can contribute to arising and exacerbation of CPP. The presence of thick adhesions could represent a marker of easy reforming lesions and consequently lesion associated CPP, respect to thin adhesions [69]. Moreover, deep dyspareunia is strongly correlated with the presence of dense pelvic adhesions [70]. About this, a Cochrane review [71] stated that adhesiolysis was not associated with an improved outcome on CPP apart from where adhesions were severe. Confirming this finding, Li et al. [72] analyzing 662 patients with endometrioma and pelvic adhesion undergoing laparoscopic ovarian endometrioma excision, found that endometrioma adhesion rate is related to severer pelvic pain symptoms, and that postoperative pain recurrence rate is more frequent in patients with moderate-to-severe endometriotic adhesion. Moreover, DIE lesion excision seems to have more effectiveness in long-term pain relief [53] respect to treatment of endometriomas and superficial peritoneal endometriosis [25,73]. Nevertheless, there is evidence that the superficial peritoneal lesions and adhesions, if not excised, represent a risk of CPP recurrence [69]. Regarding to the various surgical techniques that could be used, the Laparoscopic Utero-Sacral Nerve Ablation (LUNA) and the Presacral Neurectomy (PNS) seem to be effective to manage CPP, although pain recurrence are very frequent. Vercellini et al. [74] suggests that presacral neurectomy and amputation of the uterosacral ligaments seems to be ineffective to treat endometriosis-related CPP and does not demonstrate better results with the use of lasers rather than electrocoagulation. Also others agree with these assumptions [75], and moreover suggest using LUNA also for control of chronic pelvic pain without evidence of endometriosis. Confirming this result, Johnson et al. [76] found that there is a significant reduction in dysmenorrhea at 12 months follows up in women with chronic pelvic pain in the absence of endometriosis who underwent LUNA, but no significant difference in non-menstrual pelvic pain, deep dyspareunia or dyschezia. About the comparison between the two techniques, it seems that the short term results for PSN and LUNA seem to be similar, although PSN has better results in the long term [77]. Some good results about PSN came from data of Jedrzejczak et al. [78] and Zullo et al. [79] who evidenced that this technique could promote long-term pain relief. Kanazi et al. [80] suggest also another surgical nerve-blocking technique to treat endometriosis-related CPP: they blocked superior hypogastric plexus (SHP) and found that all patients had significant pain relief immediately after the block, although the pain scores postblock ranged from 0 to 4/10 and the duration of pain relief varied from 1 to 14 days. In order to allow easier, safer, and more accurate needle placement in SHP, Waldman et al. [81] use a single needle placed under computed tomography guidance. About this, as last standing solution, Kapural et al. [82] suggest to use the spinal cord stimulation (SCS) to treat chronic pelvic pain of visceral origin: they found, after this technique,

a reduction of the Pain Disability Index (PDI) score and of the opioid drug use. Same conclusion about this technique seems to be shared by Martellucci et al. [83] Finally, like is evidenced by Carter [84], with application of all currently available laparoscopic modalities, 80% of women with chronic pelvic pain will report a decrease of pain to tolerable levels, a significant average reduction which is maintained in 3-year follow-up.

## Alternative Therapies

Some patients affect by CPP could have an aetiology derived from psychiatric diseases that vent their devastating symptoms on the pelvic area, from drug addiction or rebound phenomena to the drug use. The physician who approaches women with CPP must also keep in mind that it is often associated to migraine and headache, regardless if related or not to endometriosis [85]. Moreover, patients with diffuse abdominal/pelvic pain had more traumas and worse mental and physical health status compared with patients with vulvovaginal pain and cyclic pain, and also had poorer health than patients with neuropathic and fibroid pain [86]. So, when all possible anatomical/functional causes of CPP are excluded, is recommended to address patient to counseling or psychotherapy [71,87], although Others [84] suggest however to address patients affected by endometriosis-related CPP to this approach because pain could be due, at least in part, to psychological features. About this, it was showed that there are no differences in mood symptoms or personality characteristics between patients with endometriosis-related CPP and with CPP not associated with endometriosis, but women with endometriosis had more severe pain and greater social dysfunction than those with unexplained pain [88]. Confirming this, Lorençatto et al. [89] evaluated 100 women with endometriosis, equally divided into one group suffering from CPP and the other pain-free. Using Beck Depression Inventory (BDI), they detected depression in 86 and 38% of the women with and without chronic pelvic pain, respectively, and so they concluded that depression is highly prevalent in women with endometriosis, especially those with pelvic pain. On the light of these results, it is widely accepted that biobehavioral techniques such as relaxation and biofeedback can help patients modifying their experience of pain [90]. Finally, some authors [91] suggest that electrodermal measures at Jing-Well acupuncture points ("indicator" points located at the tips of fingers and toes) are associated with clinical outcome in adolescent women with endometriosis-related CPP, and that acupuncture treatments could reduce this important symptoms.

## Conclusion

The endometriosis nowadays seems to stand out among the causes of this pain syndrome, although currently the efforts of the medical world are intended to clarify clearly and definitively the causal relationship between the two diseases. It seems, in fact, that the phenomena induced by endometriosis in the pelvis, including the breakdown of peritoneal homeostasis and the induction of the production of proinflammatory and proangiogenic cytokines, are responsible of altered innervations and modulation of pain pathways in these patients. Although the good results achieved so far, there is necessity of more efforts to create new non-invasive strategies that set a more accurate diagnosis of the causes of endometriosis-related CPP, in order to improve and address the best pathway to manage this painful syndrome.

## References

1. Vercellini P, Somigliana E, Vigano P, Abbiati A, Barbara G, et al. (2009) Chronic pelvic pain in women: etiology, pathogenesis and diagnostic approach. *Gynecol Endocrinol* 25: 149-158.
2. Mathias SD, Kuppermann M, Liberman RF, Lipschutz RC, Steege JF (1996) Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. *Obstet Gynecol* 87: 321-327.
3. Peters AA, van Dorst E, Jellis B, van Zuuren E, Hermans J, et al. (1991) A randomized clinical trial to compare two different approaches in women with chronic pelvic pain. *Obstet Gynecol* 77: 740-744.
4. Neis KJ, Neis F (2009) Chronic pelvic pain: cause, diagnosis and therapy from a gynaecologist's and an endoscopist's point of view. *Gynecol Endocrinol* 25: 757-761.
5. Howard FM (2003) Chronic pelvic pain. *Obstet Gynecol* 101: 594-611.
6. Chung MK, Chung RP, Gordon D (2005) Interstitial cystitis and endometriosis in patients with chronic pelvic pain: The "Evil Twins" syndrome. *JSL* 9: 25-29.
7. Stanford EJ, Koziol J, Feng A (2005) The prevalence of interstitial cystitis, endometriosis, adhesions, and vulvar pain in women with chronic pelvic pain. *J Minim Invasive Gynecol* 12: 43-49.
8. Giudice LC, Kao LC (2004) Endometriosis. *Lancet* 364: 1789-1799.
9. Baldi A, Campioni N, Signorile PG (2008) Endometriosis: pathogenesis, diagnosis, therapy and association with cancer. *Oncol Rep* 19: 843-846.
10. Bulun SE (2009) Endometriosis. *N Engl J Med* 360: 268-279.
11. Westney OL, Amundsen CL, McGuire EJ (2000) Bladder endometriosis: conservative management. *J Urol* 163: 1814-1817.
12. Trașcă ET, Trașcă E, Tițu A, Riza ML, Busuioic I (2012) Ureteral stenosis due to endometriosis. *Rom J Morphol Embryol* 53: 433-437.
13. Butticiè S, Laganà AS, Barresi V, Inferriera A, Mucciardi G, et al. (2013) Lumbar Ureteral Stenosis due to Endometriosis: Our Experience and Review of the Literature. *Case Rep Urol* 2013: 812475.
14. Shook TE, Nyberg LM (1988) Endometriosis of the urinary tract. *Urology* 31: 1-6.
15. Sinder C, Dochat GR, Wentsler NE (1965) Splenoendometriosis. *Am J Obstet Gynecol* 92: 883-884.
16. Saadat-Gilani K, Bechmann L, Frilling A, Gerken G, Canbay A (2007) Gallbladder endometriosis as a cause of occult bleeding. *World J Gastroenterol* 13: 4517-4519.
17. Kyamidis K, Lora V, Kanitakis J (2011) Spontaneous cutaneous umbilical endometriosis: report of a new case with immunohistochemical study and literature review. *Dermatol Online J* 17: 5.
18. No authors listed (1997) Revised American Society for Reproductive Medicine classification of endometriosis: 1996. *Fertil Steril* 67: 817-821.
19. Koninckx PR, Meuleman C, Demeyere S, Lesaffre E, Cornillie FJ (1991) Suggestive evidence that pelvic endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic pain. *Fertil Steril* 55: 759-765.
20. Huhtinen K, Perheentupa A, Poutanen M, Heikinheimo O (2011) Pathogenesis of endometriosis. *Duodecim* 127: 1827-1835.
21. Marana R, Lecca A, Biscione A, Muzii EL (2012) Endometriosis: the gynecologist's opinion. *Urologia* 79: 160-166.
22. Stratton P, Berkley KJ (2011) Chronic pelvic pain and endometriosis: translational evidence of the relationship and implications. *Hum Reprod Update* 17: 327-346.
23. Fauconnier A, Fritel X, Chapron C (2009) Endometriosis and pelvic pain: epidemiological evidence of the relationship and implications. *Gynecol Obstet Fertil* 37: 57-69.
24. Fauconnier A, Chapron C (2005) Endometriosis and pelvic pain: epidemiological evidence of the relationship and implications. *Hum Reprod Update* 11: 595-606.
25. Fauconnier A, Chapron C, Dubuisson JB, Vieira M, Dousset B, et al. (2002) Relation between pain symptoms and the anatomic location of deep infiltrating endometriosis. *Fertil Steril* 78: 719-726.
26. Triolo O, Laganà AS, Sturlese E (2013) Chronic pelvic pain in endometriosis: an overview. *J Clin Med Res* 5: 153-163.
27. Szendei G, Hernádi Z, Dévényi N, Csapó Z (2005) Is there any correlation between stages of endometriosis and severity of chronic pelvic pain? Possibilities of treatment. *Gynecol Endocrinol* 21: 93-100.

28. Vercellini P, Trespidi L, De Giorgi O, Cortesi I, Parazzini F, et al. (1996) Endometriosis and pelvic pain: relation to disease stage and localization. *Fertil Steril* 65: 299-304.
29. De Wilde RL, Brölmann H, Koninckx PR, Lundorff P, Lower AM, et al. (2012) Prevention of adhesions in gynaecological surgery: the 2012 European field guideline. *Gynecol Surg* 9: 365-368.
30. Howard FM (2000) The role of laparoscopy as a diagnostic tool in chronic pelvic pain. *Baillieres Best Pract Res Clin Obstet Gynaecol* 14: 467-494.
31. Porpora MG, Koninckx PR, Piazzè J, Natili M, Colagrande S, et al. (1999) Correlation between endometriosis and pelvic pain. *J Am Assoc Gynecol Laparosc* 6: 429-434.
32. Lukanova M, Popov I, Velkova A (2007) Comparison and analysis of pain profiles in women with endometriosis and pelvic congestion syndrome-part II. *Akush Ginekol (Sofia)* 46: 38-47.
33. Arruda MS, Petta CA, Abrão MS, Benetti-Pinto CL (2003) Time elapsed from onset of symptoms to diagnosis of endometriosis in a cohort study of Brazilian women. *Hum Reprod* 18: 756-759.
34. Howard FM (2009) Endometriosis and mechanisms of pelvic pain. *J Minim Invasive Gynecol* 16: 540-550.
35. Bulun SE, Cheng YH, Pavone ME, Yin P, Imir G, et al. (2010) 17Beta-hydroxysteroid dehydrogenase-2 deficiency and progesterone resistance in endometriosis. *Semin Reprod Med* 28: 44-50.
36. Pabona JM, Simmen FA, Nikiforov MA, Zhuang D, Shankar K, et al. (2012) Krüppel-like factor 9 and progesterone receptor coregulation of decidualizing endometrial stromal cells: implications for the pathogenesis of endometriosis. *J Clin Endocrinol Metab* 97: 376-392.
37. Berkley KI, Rapkin AJ, Papka RE (2005) The pains of endometriosis. *Science* 308: 1587-1589.
38. Anaf V, Simon P, El Nakadi I, Fayt I, Buxant F, et al. (2000) Relationship between endometriotic foci and nerves in rectovaginal endometriotic nodules. *Hum Reprod* 15: 1744-1750.
39. Cheng JK, Ji RR (2008) Intracellular signaling in primary sensory neurons and persistent pain. *Neurochem Res* 33: 1970-1978.
40. Quinn MJ, Kirk N (2002) Differences in uterine innervation at hysterectomy. *Am J Obstet Gynecol* 187: 1515-1519.
41. Wang G, Tokushige N, Markham R, Fraser IS (2009) Rich innervation of deep infiltrating endometriosis. *Hum Reprod* 24: 827-834.
42. Tulandi T, Felemban A, Chen MF (2001) Nerve fibers and histopathology of endometriosis-harboring peritoneum. *J Am Assoc Gynecol Laparosc* 8: 95-98.
43. Raab S, Plate KH (2007) Different networks, common growth factors: shared growth factors and receptors of the vascular and the nervous system. *Acta Neuropathol* 113: 607-626.
44. Laganà AS, Sturlese E, Retto G, Sofo V, Triolo O (2013) Interplay between Misplaced Müllerian-Derived Stem Cells and Peritoneal Immune Dysregulation in the Pathogenesis of Endometriosis. *Obstet Gynecol Int* 2013: 527041.
45. Laganà AS, D'Ascola A, Salmeri FM, Sofo V, Pizzo A, et al. (2012) mRNA expression of Foxp3 and RORc transcription factors and of IL-10 and IL-17A cytokines in ovarian endometrioma of women with endometriosis. *Journal of Endometriosis* 4: 227-228.
46. Laganà AS, Pizzo A, D'Ascola A, Salmeri FM, Sofo V, et al. (2013) mRNA expression of transcription factors and cytokines in immune cells of ovarian endometrioma from women with endometriosis. *Reproductive Sciences* 20: 146-147.
47. Pizzo A, Salmeri FM, Ardita FV, Sofo V, Tripepi M, et al. (2002) Behaviour of cytokine levels in serum and PF of women with endometriosis. *Gynecol Obstet Invest* 54: 82-87.
48. Laganà AS, Salmeri FM, Retto G, Sturlese E, Pizzo A, et al. (2012) Stage-related changes of peritoneal soluble TNF $\alpha$  and TNFR1 and TNFR2 in cells recovered from PF of women with endometriosis. *J Reprod Immunol* 94: 94-95.
49. Sturlese E, Salmeri FM, Retto G, Pizzo A, De Dominicis R, et al. (2011) Dysregulation of the Fas/FasL system in mononuclear cells recovered from PF of women with endometriosis. *J Reprod Immunol* 92: 74-81.
50. Davis L, Kennedy SS, Moore J, Prentice A (2007) Modern combined oral contraceptives for pain associated with endometriosis. *Cochrane Database Syst Rev* (3): CD001019.
51. Selak V, Farquhar C, Prentice A, Singla A (2007) Danazol for pelvic pain associated with endometriosis. *Cochrane Database Syst Rev* (4): CD000068.
52. Prentice A, Deary AJ, Bland E (2000) Progestagens and antiprogestagens for pain associated with endometriosis. *Cochrane Database Syst Rev* (2): CD002122.
53. Gambone JC, Mittman BS, Munro MG, Scialli AR, Winkel AC (2002) Consensus statement for the management of chronic pelvic pain and endometriosis: proceedings of an expert-panel consensus process. *Fertil Steril* 78: 961-972.
54. Vercellini P, Fedele L, Pietropaolo G, Frontino G, Somigliana E, et al. (2003) Progestogens for endometriosis: forward to the past. *Hum Reprod Update* 9: 387-396.
55. Ling FW (1999) Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. *Pelvic Pain Study Group. Obstet Gynecol* 93: 51-58.
56. Bahamondes L, Petta CA, Fernandes A, Monteiro I (2007) Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea. *Contraception* 7: 134-139.
57. Wu MY, Ho HN (2003) The role of cytokines in endometriosis. *Am J Reprod Immunol* 49: 285-296.
58. Braundmeier AG, Nowak RA (2006) Cytokines regulate matrix metalloproteinases in human uterine endometrial fibroblast cells through a mechanism that does not involve increases in extracellular matrix metalloproteinase inducer. *Am J Reprod Immunol* 56: 201-214.
59. Bruner-Tran KL, Eisenberg E, Yeaman GR, Anderson TA, McBean J, et al. (2002) Steroid and cytokine regulation of matrix metalloproteinase expression in endometriosis and the establishment of experimental endometriosis in nude mice. *J Clin Endocrinol Metab* 87: 4782-4791.
60. D'Hooghe TM, Nugent NP, Cuneo S, Chai DC, Deer F, et al. (2006) Recombinant human TNFRSF1A (r-hTBP1) inhibits the development of endometriosis in baboons: a prospective, randomized, placebo- and drug-controlled study. *Biol Reprod* 74: 131-136.
61. Falconer H, Mwenda JM, Chai DC, Wagner C, Song XY, et al. (2006) Treatment with anti-TNF monoclonal antibody (c5N) reduces the extent of induced endometriosis in the baboon. *Hum Reprod* 21: 1856-1862.
62. Kyama CM, Overbergh L, Mihalyi A, Meuleman C, Mwenda JM, et al. (2008) Endometrial and peritoneal expression of aromatase, cytokines, and adhesion factors in women with endometriosis. *Fertil Steril* 89: 301-310.
63. Maia H Jr, Haddad C, Coelho G, Casoy J (2012) Role of inflammation and aromatase expression in the eutopic endometrium and its relationship with the development of endometriosis. *Womens Health (Lond Engl)* 8: 647-658.
64. Cheong Y, Tay P, Luk F, Gan HC, Li TC, et al. (2008) Laparoscopic surgery for endometriosis: How often do we need to re-operate? *J Obstet Gynaecol* 28: 82-85.
65. Fleisch MC, Xafis D, De Bruyne F, Hucke J, Bender HG, et al. (2005) Radical resection of invasive endometriosis with bowel or bladder involvement - long-term results. *Eur J Obstet Gynecol Reprod Biol* 123: 224-229.
66. Chopin N, Vieira M, Borghese B, Foulot H, Dousset B, et al. (2005) Operative management of deeply infiltrating endometriosis: results on pelvic pain symptoms according to a surgical classification. *J Minim Invasive Gynecol* 12: 106-112.
67. Sutton CJ, Ewen SP, Whitelaw N, Haines P (1994) Prospective, randomized, double-blind, controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild, and moderate endometriosis. *Fertil Steril* 62: 696-700.
68. Sinaii N, Cleary SD, Younes N, Ballweg ML, Stratton P (2007) Treatment utilization for endometriosis symptoms: a cross-sectional survey study of lifetime experience. *Fertil Steril* 87: 1277-1286.
69. Parker JD, Sinaii N, Segars JH, Godoy H, Winkel C, et al. (2005) Adhesion formation after laparoscopic excision of endometriosis and lysis of adhesions. *Fertil Steril* 84: 1457-1461.
70. Milingos S, Protopapas A, Drakakis P, Liapi A, Loutradis D, et al. (2003) Laparoscopic management of patients with endometriosis and chronic pelvic pain. *Ann N Y Acad Sci* 997: 269-273.
71. Stones RW, Mountfield J (2000) Interventions for treating chronic pelvic pain in women. *Cochrane Database Syst Rev* (4): CD000387.

72. Li XY, Leng JH, Lang JH, Dai Y, Wang YY (2009) Study on incidence and associated factors of different degree endometrioma adhesions. *Zhonghua Fu Chan Ke Za Zhi* 44: 328-332.
73. Nezhat C, Santolaya J, Nezhat FR (1994) Comparison of transvaginal sonography and bimanual pelvic examination in patients with laparoscopically confirmed endometriosis. *J Am Assoc Gynecol Laparosc* 1: 127-130.
74. Vercellini P, Fedele L, Bianchi S, Candiani GB (1991) Pelvic denervation for chronic pain associated with endometriosis: fact or fancy? *Am J Obstet Gynecol* 165: 745-749.
75. El-Din Shawki H (2011) The efficacy of laparoscopic uterosacral nerve ablation (LUNA) in the treatment of unexplained chronic pelvic pain: a randomized controlled trial. *Gynecol Surg* 8: 31-39.
76. Johnson NP, Farquhar CM, Crossley S, Yu Y, Van Peperstraten AM, et al. (2004) A double-blind randomized controlled trial of laparoscopic uterine nerve ablation for women with chronic pelvic pain. *BJOG* 111: 950-959.
77. Cheong Y, William Stones R (2006) Chronic pelvic pain: aetiology and therapy. *Best Pract Res Clin Obstet Gynaecol* 20: 695-711.
78. Jedrzejczak P, Sokalska A, Spaczynski RZ, Duleba AJ, Pawelczyk L (2009) Effects of presacral neurectomy on pelvic pain in women with and without endometriosis. *Ginekol Pol* 80: 172-178.
79. Zullo F, Palomba S, Zupi E, Russo T, Morelli M, et al. (2004) Long-term effectiveness of presacral neurectomy for the treatment of severe dysmenorrhea due to endometriosis. *J Am Assoc Gynecol Laparosc* 11: 23-28.
80. Kanazi GE, Perkins FM, Thakur R, Dotson E (1999) New technique for superior hypogastric plexus block. *Reg Anesth Pain Med* 24: 473-476.
81. Waldman SD, Wilson WL, Kreps RD (1991) Superior hypogastric plexus block using a single needle and computed tomography guidance: description of a modified technique. *Reg Anesth* 16: 286-287.
82. Kapural L, Narouze SN, Janicki TI, Mekhail N (2006) Spinal cord stimulation is an effective treatment for the chronic intractable visceral pelvic pain. *Pain Med* 7: 440-443.
83. Martellucci J, Naldini G, Del Popolo G, Carriero A (2012) Sacral nerve modulation in the treatment of chronic pain after pelvic surgery. *Colorectal Dis* 14: 502-507.
84. Carter JE (1998) Surgical treatment for chronic pelvic pain. *JSLs* 2: 129-139.
85. Karp BI, Sinaii N, Nieman LK, Silberstein SD, Stratton P (2011) Migraine in women with chronic pelvic pain with and without endometriosis. *Fertil Steril* 95: 895-899.
86. Leserman J, Zolnoun D, Meltzer-Brody S, Lamvu G, Steege JF (2006) Identification of diagnostic subtypes of chronic pelvic pain and how subtypes differ in health status and trauma history. *Am J Obstet Gynecol* 195: 554-560.
87. D'Ercole C, Bretelle F, Heckenroth H, Cravello L, Boubli L, et al. (1995) Painful pelvic adhesion syndrome. *Rev Fr Gynecol Obstet* 90: 73-76.
88. Peveler R, Edwards J, Daddow J, Thomas E (1996) Psychosocial factors and chronic pelvic pain: a comparison of women with endometriosis and with unexplained pain. *J Psychosom Res* 40: 305-315.
89. Lorençatto C, Petta CA, Navarro MJ, Bahamondes L, Matos A (2006) Depression in women with endometriosis with and without chronic pelvic pain. *Acta Obstet Gynecol Scand* 85: 88-92.
90. Greco CD (2003) Management of adolescent chronic pelvic pain from endometriosis: a pain center perspective. *J Pediatr Adolesc Gynecol* 16: 17-19.
91. Ahn AC, Schnyer R, Conboy L, Laufer MR, Wayne PM (2009) Electrodermal Measures of Jing-Well Points and Their Clinical Relevance in Endometriosis-Related Chronic Pelvic Pain. *J Altern Complement Med* 15: 1293-1305.